コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Treatment with 20% beeswax was the most suitable for industri
2 Treatment with 3P10 reverses excessive lipid oxidation in tum
3 Treatment with adipogenic medium induced a significant increm
4 Treatment with aminoglycosides such as streptomycin or gentam
5 Treatment with anti-vascular endothelial growth factor agents
6 Treatment with icatibant (bradykinin-B2-antagonist) or anakin
7 Treatment with lovastatin, a mevalonate biosynthesis inhibito
8 Treatment with naked anti-CD26 mAb KU44.13A did not have any
9 Treatment with Tat-A and Tat-B caused membrane disruption and
10 Treatment with the CSF1R inhibitor GW2580 significantly atten
11 Treatment with TNF inhibitors in RA patients reverses the exp
14 ementia, but these changes are attenuated or reversed after treatment with the DDR1 inhibitor, nilotinib.
15 Rab27b KD also decreased LC3 turnover after treatment with an autophagosome-lysosome fusion inhibitor, ch
17 tissues and in response to environmental stressors such as treatment with heat, chemicals, or virus elicitors of UPR.
18 ing of reduced child mortality in communities with biannual treatment with azithromycin remain unclear.
19 monthly) from 12 cAMR patients who failed standard of care treatment with intravenous immune globulin + rituximab with o
20 ced GSL and monosialotetrahexosylganglioside levels, and co-treatment with standard chemotherapeutics sensitized cells to
22 sistent benefits for subgroups based on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but suggested treat
28 g/L Zn and 2.81 g/L Cu, which was subjected to hydrothermal treatment with the addition of levulinic acid (LA).
30 V infections, it has been hypothesized that the benefits of treatment with renin-angiotensin system inhibitors in SARS-Co
31 e best of our knowledge, this is the first reported case of treatment with retrobulbar triamcinolone injections.
33 IV infection, as these cells can persist despite decades of treatment with antiretroviral therapy (ART).
35 ed high-dose melphalan and stem cell transplantation and/or treatment with a proteasome inhibitor.
36 or PH is unknown.Objectives: To evaluate whether postnatal treatment with rhIGF-1 (recombinant human IGF-1)/BP3 (binding
38 homa, who relapsed or had refractory disease after previous treatment with one to three systemic regimens (with at least
41 ient with schwannomatosis-associated N/S HNST, and targeted treatment with the small-molecule ERBB inhibitor lapatinib le
43 ve and P50 inhibition deficits, suggesting that longer term treatment with alpha7 nAChR agonists for these deficits in SC
46 histologic assessment of retinal morphology, we found that treatment with these flavonoids prior to light insult remarka
49 suffering from ulcerative colitis (UC), in which first-time treatment with vedolizumab was initiated.
50 ssel and/or left main coronary artery disease randomized to treatment with PCI or CABG in the SYNTAX trial.